The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors

References 

1. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med. 1981;305:612–618
   • MEDLINE
   • CrossRef
2. Samsioe G, Mattsson LA. Some aspects of the relationship between oral contraceptives, lipid abnormalities and cardiovascular disease. Am J Obstet Gynecol. 1990;163:354–358
   • Abstract
   • Full-Text PDF (654 KB)
3. Melis GB, Fruzzetti F, Nicoletti I, Ricci C, Lammers P, Atsma WJ, et al.  A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinyl estradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestogen on coagulatory factors. Contraception. 1991;43:23–31
   • Abstract
   • Full-Text PDF (557 KB)
   • CrossRef
4. Daly I, Bonnar J. Comparative studies of 30 μg ethinyl estradiol combined with gestogen and desogestrel on blood coagulation, fibrinolysis, and platelets. Am J Obstet Gynecol. 1990;163:430–437
   • Abstract
   • Full-Text PDF (534 KB)
5. Sabra A, Bonnar J. Hemostatic changes induced by 50 μg and 30 μg oestrogen/progestogen oral contraceptives. J Reprod Med. 1983;28:85–91
   • MEDLINE
6. Castillo JB, Farag AM, Mammen EF, Sachs RJ. Prothrombin times and clottable fibrinogen determination on an Automated Coagulation Laboratory (ACL-810). Thromb Res. 1989;55:213–219
   • Abstract
   • Full-Text PDF (479 KB)
   • CrossRef
7. Mammen EF, Farag AM, Ozawa T. Gerinnungsbestimmungen am Zentrifugalanalysator: Messung mit chromogenen Substraten und mit der Fibringerinnung. Haemostasesologie. 1991;11:8–11
8. Hirokawa S, Mammen EF. A functional protein S and microlatex immunoassay for protein S and C4b-binding protein on the Automated Coagulation Laboratory (ACL) 300 Plus. Clin Appl Thromb Hemost. 1996;2:268–275
   • CrossRef
9. Basdevant A, Conard J, Pelissier C, Guyene TT, Lapousterle C, Mayer M, et al.  Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 μg to 20 μg in oral contraceptives containing desogestrel. Contraception. 1993;48:193–204
   • Abstract
   • Full-Text PDF (299 KB)
   • CrossRef
10. Winkler UH, Schindler AE, Endrikat J, Dusterberg B. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinyl estradiol. Contraception. 1996;53:75–84
    • Abstract
    • Full-Text PDF (1027 KB)
    • CrossRef
11. Winkler UH, Holscher T, Shulte H, Zierleyn JP, Collet W, Schindler AE. Ethinyl estradiol 20 versus 30 μg combined with 150 μg desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system. Gynecol Endocrinol. 1996;10:265–271
    • MEDLINE
    • CrossRef
12. Winkler UH. Effects on hemostatic variables of desogestrel- and gestogen-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review. Am J Obstet Gynecol. 1998;179:S51–S61
    • Abstract
    • Full Text
    • Full-Text PDF (79 KB)
    • CrossRef
13. Winkler UH, Oberoff C, Bier U, Schindler AE, Gillain D. Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestogen or norgestimate: an open randomized parallel-group study. Int J Fertil. 1995;40:260–268
14. Norris L, Bonnar J. The effect of oestrogen dose and progestogen type on hemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol. 1996;103:261–267
    • MEDLINE
15. Quehenberger P, Kapiotis S, Partan C, Schneider B, Wenzel R, Gaiger A, et al.  Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells. Ann Hematol. 1993;67:33–36
    • MEDLINE
    • CrossRef
16. Gram J, Munkvad S, Jespersen J. Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in estrogen. Am J Obstet Gynecol. 1990;163:430–442
    • Abstract
    • Full-Text PDF (534 KB)
17. Winkler UH, Koslowski S, Schindler AE. PAI activity is reduced in users or oral contraceptives-influence of estrogen content [abstract]. Thromb Haemost. 1989;62:394